Numerous clinical and environmental conditions result in elevated thrombin generation with subsequent thrombus formation not only in adults but also in children ([@b2-ehp0116-000839]; [@b34-ehp0116-000839]). Both genetic and environmental factors have been established as causes of cardiovascular disease (CVD)---for example, coronary heart disease, stroke, and deep venous thrombosis (DVT) ([@b10-ehp0116-000839]; [@b41-ehp0116-000839]). Stroke in children is a rare disease with an estimated incidence of 2.6 per 100,000 per year ([@b35-ehp0116-000839]), with half of the events reported presenting as acute ischemic strokes (AISs). Risk factors of AIS in children include congenital heart malformations, vascular abnormalities, endothe-lial damage, infectious diseases, and collagen tissue diseases, as well as some rare inborn metabolic disorders ([@b18-ehp0116-000839]; [@b28-ehp0116-000839]). In addition, it has recently been demonstrated that hyper-coagulable states associated with *a*) the presence of the factor (F) V G1691A mutation, the FII G20210A variant, *b*) increased concentrations of lipoprotein(a) \[Lp(a)\], and *c*) deficiency states of antithrombin, protein C, protein S, and tissue factor pathway inhibitor (TFPI) represent risk factors for AIS in childhood ([@b9-ehp0116-000839]; [@b13-ehp0116-000839]; [@b16-ehp0116-000839]; [@b29-ehp0116-000839], [@b30-ehp0116-000839]; [@b42-ehp0116-000839]). In addition, measurable risk factors for CVD in adults further include traits such as obesity, high blood pressure, elevated serum cholesterol, and low levels of high-density lipoprotein (HDL), with an aggregation within families ([@b12-ehp0116-000839]; [@b21-ehp0116-000839]; [@b39-ehp0116-000839]). These studies suggest that genetic factors are important in determining CVD. In adult cohorts, however, there is increasing evidence that in addition to genetic risk factors influ-encing lipid and coagulation factor levels, modifiable environmental factors such as smoking, alcohol consumption, diet, or exercise are likely to contribute to the pathogenesis of CVD ([@b7-ehp0116-000839]; [@b25-ehp0116-000839]; [@b27-ehp0116-000839]; [@b31-ehp0116-000839]). Developing statistical methodology allows investigation of traits whose susceptibility to familial influences impinges on the risk of diseases at interest ([@b1-ehp0116-000839]). The identifica-tion of heritable and environmental factors possibly influencing a condition at risk should be a prerequisite for the search for *a*) quantitative trait loci affecting such traits and *b*) household effects modulating the risk of disease. Thus far, such epidemiologic approaches in various population cohorts of different size---for example, healthy twins ([@b3-ehp0116-000839]; [@b8-ehp0116-000839]; [@b15-ehp0116-000839]; [@b24-ehp0116-000839]; [@b37-ehp0116-000839]), Spanish idiopathic thrombosis families ([@b38-ehp0116-000839]), relatives of protein C--deficient pedigrees ([@b44-ehp0116-000839]), or parent--offspring pairs from national health surveys ([@b11-ehp0116-000839]; [@b33-ehp0116-000839])---have been performed mainly in adult cohorts. Although these studies included pediatric offspring, they did not focus primarily on pediatric disease. To date, such studies in families with first onset of stroke during early childhood are lacking. Because estimates for heritability may provide insights into the relative importance of genetic and environmental variables associated with AIS in children, the present study was conducted.

Methods
=======

Ethics
------

The present study was performed in accordance with the ethical standards laid down in the updated version of the 1964 Declaration of Helsinki ([@b45-ehp0116-000839]) and was approved by the medical ethics committee of the University of Münster, Germany. With written parental consent, term neonates and children with confirmed diagnosis of AIS who were ≤ 18 years of age at onset, biological brothers and sisters, and available parents (nuclear family) were enrolled.

Study population and study design
---------------------------------

From July 1996 to August 2006, 1,002 household members of 282 white pediatric index patients enrolled in the Münster stroke database were analyzed ([@b9-ehp0116-000839]; [@b30-ehp0116-000839]; [@b42-ehp0116-000839]). AIS was con-firmed by standard imaging methods---duplex sonography, magnetic resonance imaging, and computerized tomography, and/or magnetic resonance angiography ([@b30-ehp0116-000839]; [@b42-ehp0116-000839]). All family members enrolled were personally interviewed regarding their medical history, surgery, trauma, immobilization, infections, pregnancies, and use of any medication such as oral contraceptives, hormone replacement therapy, antibiotics, lipid-lowering therapy, and antihypertensive or antidiabetic drugs. In addition, data on objectively confirmed thromboembolic events including age at onset, triggering factors, imaging methods performed, and use of antithrombotic/antiplatelet therapy and its duration were documented. Preterm AIS infants and patients \> 18 years of age at first AIS onset were not included in the present study. In addition, patients with suspected AIS without the diagnosis being confirmed by an independent experienced pediatric neuroradiologist were excluded from the present survey. Seven adult patients using vitamin K antagonists were excluded from the analysis for vitamin K--dependent coagulation proteins, D-dimer, and prothrombin F1.2. In addition, we excluded 18 parents from the analysis for lipid measurements who were taking lipid-lowering medication.

Blood sample collection
-----------------------

We collected blood samples from patients and relatives in the morning after a 12-hr fasting period (for infants, 4--6 hr); samples were drawn by peripheral venipuncture into plastic tubes containing 1/10 by volume of 3.8% trisodium citrate (Sarstedt, Nümbrecht, Germany) and were immediately placed on melting ice. Serum plastic tubes purchased from Sarstedt were used to collect samples to measure lipid components. The blood samples from patients were collected 6--12 months after the acute thrombotic event and at least 6 weeks apart from anticoagulation. Platelet-poor plasma or serum was prepared by centrifugation at 3,000 × *g* and 4°C for 2 × 20 min, aliquoted in polystyrene tubes, stored at --70°C, and thawed immediately before assay. DNA extraction was performed by a spin column procedure (QIAGEN GmbH, Hilden, Germany) as previously described ([@b17-ehp0116-000839]). For the present study, blood samples were drawn from otherwise healthy patients, relatives, and controls with normal hemograms and no evidence of further diseases.

Laboratory analyses
-------------------

With written parental consent, laboratory analyses including Lp(a), kringle 4 repeats, total cholesterol, low-density lipoprotein (LDL), HDL, the FV G1691A mutation, the FII G20210A variant, fibrinogen, FV, chromogenic FII, FVIIIC, von Willebrand factor (vWF) antigen, antithrombin, protein C, free protein S, protein Z, plasminogen, total TFPI, D-dimer, prothrombin fragment f1.2 (f1.2), and antiphospholipid antibodies/lupus anticoagulants were performed as previously described ([@b14-ehp0116-000839]; [@b17-ehp0116-000839]; [@b20-ehp0116-000839]; [@b29-ehp0116-000839], [@b30-ehp0116-000839]; [@b32-ehp0116-000839]). Based on the availability of appropriately stored serum and plasma samples, the number of individuals per assay varied from 582 to 1,002.

Statistics
----------

Statistical analyses were performed using the StatView 5 (SAS Institute Inc., Cary, NC, USA) and SOLAR software packages ([@b1-ehp0116-000839]). Because nonparametric tests are less dependent on the shape of the underlying distributions, continuous data are presented as medians (minimum--maximum) and are evaluated statistically by using the Wilcoxon--Mann--Whitney *U* test or Kruskal--Wallis test, corrected for multiple testing according to Bonferroni. On the assumption that multiple genes with small effects influence pediatric AIS, as well as the premise of having normally distributed traits, we estimated heritability (h^2^r) for lipid concentrations and coagulation factor levels using the variance component method implemented in SOLAR. This method allows the total phenotypic variance to be partitioned into a proportion caused by polygenic effects and a proportion caused by random environmental effects, including the proportion of variance in a trait that can be attributed to common environmental factors/ household effects (c^2^). The calculated h^2^r thus estimates the total variance of a trait explained by additive genetic effects. Before variance component analysis, we tested the phenotypic distribution using the Kolmogorov--Smirnov test to assure normal distribution of the trait within the population, as required for parametric analytic procedures. Traits failing the requirements of normality in the Kolmogorov--Smirnov test were transformed through a logarithmic transformation and retested for normalcy. All traits were normally distributed except for Lp(a), which was subsequently logarithmically transformed and then passed the Kolmogorov--Smirnov test for normalcy. To adjust for covariates possibly explaining the phenotypic h^2^r or c^2^ variation in this pediatric AIS family study, we entered the FV G1691A mutation, the prothrombin G20210A variant, age at blood sample collection, blood group, sex, smoking, and the use of oral contraceptives, into the final model of the variance component analysis. Both variance components and covariates were estimated simultaneously by maximum likelihood techniques as implemented in SOLAR. We tested the null hypothesis of no genetic effect (h^2^r = 0) on phenotype with a likelihood ratio test by comparing the likelihood of a restricted model in which parameter h^2^r was constrained to a value of 0 with that for a general model in which the same parameter was estimated. Standard errors were calculated as part of the iterations preceding the variance component analysis. Because our samples were ascertained via index patients, we conditioned the likelihood of a family on a phenotype of the initial proband to account in part for the nonrandom sampling ([@b6-ehp0116-000839]) as implemented in SOLAR. We calculated prevalence rates of prothrombotic risk factors in patients and family members by descriptive statistics and compared them by chi-square analysis or by Fisher's exact test, if appropriate. The criterion for statistical significance was set at α = 0.05. *p*-Values were based on two-sided test.

Results
=======

Study population
----------------

One thousand two subjects were recruited and examined from 282 pedigrees and households including 498 children; the structure of pedigrees varied from 3 to 10 individuals, with a median of three family members sharing one household. The main characteristics of the 1,002 family members are shown in [Table 1](#t1-ehp0116-000839){ref-type="table"}. The median age of the index patients was 4 years, and the whole population, of which 50.6% members were male, had a median age of 22 years. Whereas sex, body mass index (BMI), and the proportion of prothrombotic risk factors did not differ significantly between the offspring groups, age at blood sample collection and the rate of smoking was significantly increased in parents. [Table 2](#t2-ehp0116-000839){ref-type="table"} describes median (minimum--maximum) values of the lipid concentrations and coagulation factors investigated. Again, there was no statistical difference between the pediatric groups tested. In contrast, as expected, median (minimum--maximum) values of cholesterol, LDL, FII, protein C, protein Z, and plasminogen were significantly higher in parents compared with their offspring.

Heritability analysis
---------------------

When we measured h^2^r without accounting for possible environmental effects, h^2^r estimates were highly significant for lipid concentrations and coagulation factor levels investigated except for F1.2. The significant proportion of phenotypic variance explained by h^2^r ranged from 11.8% for cholesterol to 78.8% for Lp(a) kringle 4 repeats \[Supplemental Material, [Table 1](#t1-ehp0116-000839){ref-type="table"} (online at <http://www.ehponline.org/members/2008/10754/suppl.pdf>)\].

Heritability analysis including c^2^ estimate
---------------------------------------------

When incorporating h^2^r and c^2^ in one model adjusted for modifiers, such as the FV G1691A mutation, the FII G20210A variant, age at blood sample collection, blood group, sex, smoking, and the use of oral contraceptives in females, we found high and significant h^2^r estimates for Lp(a) serum levels, Lp(a) kringle 4 repeats, LDL, fibrinogen, protein C, and protein Z, with a corresponding phenotypic variance explained by genes of 84.3, 76.5, 24.3, 22.5, 17.7, and 42.3% respectively. In addition to the significant h^2^r estimates, c^2^ showed significant effects on phenotypic variation for fibrinogen (11.7%), protein C (20.1%), and protein Z (30.2%). A significant c^2^ effect without evidence for heritability was found for cholesterol (16.3%) and plasma levels of FII (20.8%), FV (9.3%), antithrombin (30.0%), protein S (33.2%), plasminogen (20.3%), TFPI (24.8%), and vWF (15.8%). Of note, the proportion of phenotypic variance explained by smoking alone was 4% for cholesterol, LDL, and protein S. For most of the traits under study, the model with the best fit was the household polygenic model, except for Lp(a) (polygenic model), antithrombin, D-dimer, FII, and FV (household model). The sporadic model was the best fit model to analyze prothrombin fragment 1.2. In [Table 3](#t3-ehp0116-000839){ref-type="table"}, we summarize h^2^r, c^2^ estimates, and the role of modifiers if applicable for all lipid concentrations and coagulation factors measured.

Discussion
==========

The present study was performed to identify heritability and environmental factors possibly influencing AIS in white children and their families. This is the first large-scale family study of the genetics of quantitative variation in putative risk factors associated with AIS in a cohort of children and their young parents. The highest estimates were found for measures of Lp(a) and protein Z, and lower but still significant heritabilities were seen for LDL, fibrinogen, and protein C. Our findings are in accordance with previous data obtained predominantly in adults investigated for h^2^r and c^2^ incorporated in one model ([@b25-ehp0116-000839]; [@b37-ehp0116-000839]; [@b44-ehp0116-000839]). In addition to the h^2^r estimates mentioned previously, in the present survey a significant concomitant c^2^ effect was found for protein Z, protein C, and fibrinogen. We confirmed a shared c^2^ effect for levels of vWF, which has previously been shown by [@b44-ehp0116-000839] in a large pedigree of a protein C--deficient family.

Elevated Lp(a) plays a role for first AIS in white children and also represents a risk factor for early stroke recurrence in this cohort ([@b30-ehp0116-000839]; [@b42-ehp0116-000839]). Based on the literature, heritability estimates of Lp(a) are age independent ([@b24-ehp0116-000839]; [@b37-ehp0116-000839]). Our finding is in line with the observation that Lp(a) in Europeans is determined in most cases by a single gene located on chromosome 6q26-27 ([@b36-ehp0116-000839]), identified as the major quantitative trait locus, and that at least a second locus, recently reported ([@b5-ehp0116-000839]), might be involved. [@b44-ehp0116-000839] reported on high heritability estimates for protein Z (66.7%), with an environmental effect of 6.6%. In our study, however, based mainly on the different study design, h^2^r for protein Z was lower---for example, 42.3%, with a shared c^2^ estimate of 30.2%. Although the information on protein Z heritability estimates was congruent, contradictory data have been reported for protein Z plasma levels associated with stroke in adults. On one hand, AIS was associated with low protein Z concentrations ([@b43-ehp0116-000839]); on the other hand, elevated protein Z concentrations were associated with AIS in adults ([@b19-ehp0116-000839]; [@b22-ehp0116-000839]; [@b40-ehp0116-000839]). Because the protein Z phenotypes are influenced not only by genes but also by acute-phase reactions ([@b23-ehp0116-000839]), the identifica-tion of additive genetic effects influencing the variability of this phenotype will contribute to the future understanding of the role of protein Z in adult or pediatric AIS.

The main difference of our study from previous reports is based on the additional estimation of c^2^ effects: Here we present an important influence of the shared c^2^ estimates on phenotypic variation explained by genes adjusted for FV G1691A, FII G20210A, age at blood sample collection, blood groups, sex, smoking, use of hormonal contraceptives for cholesterol, and plasma levels of FII, FV, antithrombin, protein S, plasminogen, and TFPI, with significant estimates ranging from 9.3% for FV to 33.2% for protein S. One reason for the contradictory results relating to plasma levels of FII and FV, respectively, might be the fact that in our analysis FV G1691A and FII G20210A variants were introduced as covariates in the analysis.

In our family study we included 498 children ≤ 18 years of age with a median age of 5 years, which means that the duration of the parent--offspring pair relationships was at least 5 years. Because our population differs in age and the source of CVD---pediatric AIS---from the studies previously published ([@b3-ehp0116-000839]; [@b4-ehp0116-000839]; [@b8-ehp0116-000839]; [@b15-ehp0116-000839]; [@b25-ehp0116-000839], [@b24-ehp0116-000839]; [@b31-ehp0116-000839]; [@b33-ehp0116-000839]; [@b37-ehp0116-000839]; [@b38-ehp0116-000839]; [@b44-ehp0116-000839]), our data strengthen the hypothesis that except for Lp(a) concentrations, age at investigation as well as different underlying CVDs play a role with respect to the proportion of phenotypic variance explained by additive genetic effects ([@b15-ehp0116-000839]; [@b37-ehp0116-000839]). The young AIS cohort presented here and collected in the Münster pediatric stroke database, including index children, brothers, and sisters as well as parents (nuclear families), offers the unique opportunity for longitudinal subject follow-up, scheduled at a 5-year interval to obtain additional information on genetic and environmental variations in this AIS cohort.

In addition to the attributed magnitude of the c^2^ effect and the age at recruitment, the study design chosen also influences results obtained from family-based surveys. The study populations reported so far differed not only by geographic enrollment but also by sample size and subject selection. Twin studies were performed for lipid measurements by [@b15-ehp0116-000839], [@b37-ehp0116-000839], and [@b25-ehp0116-000839], [@b24-ehp0116-000839], and heritability estimates for coagulation factors in healthy twins were measured by [@b8-ehp0116-000839] and [@b3-ehp0116-000839] in the United Kingdom. [@b38-ehp0116-000839] estimated heritability in family members of probands with idiopathic thrombophilia in Spain, and [@b44-ehp0116-000839] enrolled relatives from a large protein C--deficient family. Subject recruitment from healthy families in the United Kingdom was performed by [@b11-ehp0116-000839], and a small, two-generation pedigree study from the U.K. national health survey was recently published by [@b33-ehp0116-000839]. [Table 4](#t4-ehp0116-000839){ref-type="table"} summarizes studies measuring h^2^r as well as c^2^ ([@b3-ehp0116-000839]; [@b8-ehp0116-000839]; [@b26-ehp0116-000839]; [@b33-ehp0116-000839]; [@b38-ehp0116-000839]; [@b44-ehp0116-000839]). Thus, we suggest that the lower heritability reported in the present two-generation pedigrees of young stroke children, their parents, and siblings, with a median of three nuclear subjects per household compared with other studies, might be explained mainly by age and AIS as CVD origin.

A limitation of such a study is that a measurement error can be associated with decreased heritability estimates, as discussed by [@b38-ehp0116-000839]. The lower heritability estimates presented here, however, are unlikely to be caused by measurement error, as the intraassay coefficients of variation (ICV) and run-to-run coefficients of variation (RCV) reported for the methodologies used were small, for example, ranging from 1.3% (vWF) to 6.2% (F1.2) for ICV and 3.3% (FVIIIC) to 9.5% (F1.2) for RCV, respectively ([@b20-ehp0116-000839]). In addition, data reported here are limited to the cohort investigated---that is, white German stroke children. As outlined, our family-based study sample consists of nuclear families with one or more first-degree siblings (no half-siblings) and their parents who were ascertained via index patients. To partly accommodate the nonrandom sampling, we conditioned our analyses on the phenotype of the initial proband ([@b6-ehp0116-000839]). However, we cannot rule out that the reported estimates for h^2^r and c^2^ may be overfit and are not representative of the general population.

In conclusion, in addition to the strong heritability estimates found for Lp(a) kringle 4 repeats and Lp(a) concentrations and, to a lesser extent, for protein Z, LDL, fibrinogen, and protein C, our findings strengthen the importance of shared environmental influences of lipids and levels of coagulation factors during childhood and early adulthood, hereby pointing to the potential for family-based lifestyle interventions. Along with the diagnostic workup of known prothrombotic polymorphisms associated with stroke onset in white German children ([@b9-ehp0116-000839]; [@b29-ehp0116-000839], [@b30-ehp0116-000839]; [@b42-ehp0116-000839]), the main focus on AIS studies in this cohort will include future research to identify novel genes involved in the control of quantitative trait loci, as well as environmental risk factors with a strong c^2^ effect (such as smoking) as the main factors essential in prevention of AIS in children. Families with affected subjects are advised to change their lifestyle to reduce their CVD risk for future offspring.

Supplemental Material is available online at <http://www.ehponline.org/members/2008/10754/suppl.pdf>
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###### 

Pedigree characteristics (index children, biological siblings, and parents).

  Characteristic                                                AIS children (*n* = 282)   Siblings (*n* = 216)   Parents (*n* = 504)
  ------------------------------------------------------------- -------------------------- ---------------------- ------------------------------------------------------------------
  Disease/health status                                                                                           
   AIS/DVT/MI (no.)                                             282/---/---                3/---/---              1/8/3
   Age (years) at blood collection \[median (min--max)\]        4 (0.1--18)                6 (0.1--18)            35 (17--65)[\*](#tfn2-ehp0116-000839){ref-type="table-fn"}
   Male sex \[no. (%)\]                                         152 (54)                   115 (53)               241 (47.9)
   BMI (kg/m^2^) \[median (min--max)\]                          16.0 (7.9--30.9)           17.4 (10.8 --29.3)     24.6 (17.7--46.9)[\*](#tfn2-ehp0116-000839){ref-type="table-fn"}
  Risk factors                                                                                                    
   FVG1691A \[no. (%)\]                                         41 (14.5)                  23 (10.6)              59 (11.7)
   Prothrombin G20210A \[no. (%)\]                              19 (6.7)                   6 (2.8)                18 (3.6)
   Antithrombin-/protein C--/protein S--deficiency/APS (no.)    0/4/0/4                    0/0/0/0                0/4/0/1
   Lp(a) \> 30 mg/dL \[no. (%)\]                                72 (25.5)                  53 (24.4)              131 (26.0)
   Smoking \> 12 years of age \[no. (%)\]                       3 (1.1)                    10 (4.6)               77 (15.3)[\*](#tfn2-ehp0116-000839){ref-type="table-fn"}
   Use of oral contraceptives \[no. (%)\]                       ---                        6 (2.8)                31 (11.8)
  Therapy                                                                                                         
   Aspirin/vitamin K antagonists (no.)                          25/---                     ---/---                3/7
   Antihypertensive/antidiabetic/lipid-lowering therapy (no.)   4/0/0                      0/0/0                  75/5/18

Abbreviations: ---, no event; max, maximum; MI, myocardial infarction; min, minimum.

Compared with children, *p* \< 0.05.

###### 

Median (min--max) values of lipid and coagulation factor levels in index patients and relatives.

  Characteristic                              Individuals tested (no.)   AIS children *(n* = 282)                                       Siblings (*n* = 216)   Parents (*n* = 504)
  ------------------------------------------- -------------------------- -------------------------------------------------------------- ---------------------- ----------------------------------------------------------------
  Lipid components \[median (min--max)\]                                                                                                                       
   Lp(a) (mg/dL)                              1,002                      14 (0--168)                                                    16 (0.6--126)          18 (1--201)
   Lp(a) kringle 4 repeats                    971                        27 (12--37)                                                    25 (13--37)            27 (8--37)
   Total cholesterol (mg/dL)                  870                        161 (91--249)                                                  160 (96--222)          192 (93--323)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}
   LDL (mg/dL)                                868                        85 (24--177)                                                   87 (38--171)           111 (22--236)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}
   HDL (mg/dL)                                870                        55 (25--104)                                                   58 (29--96)            59 (27--111)
  Coagulation factors \[median (min--max)\]                                                                                                                    
   Fibrinogen (mg/dL)                         1,002                      247 (128--572)                                                 248 (36--528)          260 (136--572)
   FII (%)                                    1,002                      98 (24 --172)                                                  98 (18--164)           107 (62--201)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}
   FV (%)                                     1,002                      100 (25--195)                                                  105 (13--1074)         111 (50--182)
   FVIIIC (%)                                 934                        102 (39--192)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}   105 (59--184)          118 (34--236)
   vWF (% )                                   870                        103 (19--279)                                                  102 (25--220)          109 (38--281)
   Antithrombin (%)                           820                        103 (71--131)                                                  107 (66--136)          103 (74--150)
   Protein C (%)                              960                        89 (23--196)                                                   91 (18--174)           109 (39--200)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}
   Protein S (%)                              960                        94 (42--162)                                                   90 (38--156)           94 (35--188)
   Protein Z (μg/mL)                          582                        1.3 (0.21--8)                                                  1.4 (0.44--3.2)        1.6 (0.33--4.9)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}
   Plasminogen (%)                            934                        94 (44--135)                                                   96 (49--151)           105 (62--207)[\*](#tfn4-ehp0116-000839){ref-type="table-fn"}
   TFPI (ng/mL)                               865                        57 (21--116)                                                   40 (28--113)           47 (19--116)
   D-dimer (mg/L)                             752                        0.16 (0--0.6)                                                  0.18 (0--2.0)          0.12 (0--1.6)
   Prothrombin F1.2 (nmol/L)                  826                        0.8 (0--6.5)                                                   0.7 (0.1--4.5)         0.8 (0--8.1)

Abbreviations: max, maximum; min, minimum.

Compared with children, *p* \< 0.05.

###### 

Proportion of phenotypic variance explained by covariates (%), h^2^r, and c^2^ (% ± SE).

  Factor of interest          Covariates (%)    h^2^r ± SE    *p*-Value   c^2^ ± SE    *p*-Value[a](#tfn6-ehp0116-000839){ref-type="table-fn"}
  --------------------------- ----------------- ------------- ----------- ------------ ---------------------------------------------------------
  Lp(a)                       R                 84.3 ± 9.5    \< 0.0001   0.4 ± 6.5    0.5
  Lp(a) kringle 4 repeats     R                 76.5 ± 8.5    \< 0.0001   8.0 ± 6.7    0.11
  Cholesterol (total)         A/S (23.5)        9.3 ± 1.3     0.23        16.3 ± 6.5   0.006
  HDL                         A/G/S (10.0)      15.7 ± 14.6   0.14        9.4 ± 7.2    0.1
  LDL                         A/G/S (16.8)      24.3 ± 13.1   0.034       10.2 ± 6.6   0.060
  Fibrinogen                  A/G (2.5)         22.5 ± 12.7   0.038       11.7 ± 6.4   0.035
  FII                         A/G/FII (11.8)    0             0.5         20.8 ± 3.5   0.0001
  FV                          A (0.4)           0             0.5         9.3 ± 2.3    0.002
  FVIIIC                      A/G (3.5)         5.9 ± 1.8     0.37        12.1 ± 8.3   0.07
  vWF                         FII (0.001)       23.4 ± 16.1   0.075       15.8 ± 8.1   0.024
  Antithrombin                A (2.6.)          0             0.5         30.0 ± 3.8   \< 0.0001
  Protein C                   A (12.2)          17.7 ± 10.7   0.049       20.1 ± 5.6   0.0002
  Protein S                   A/G/S (15.2)      14.9 ± 11.6   0.099       33.2 ± 6.3   \< 0.0001
  Protein Z                   A/G/H (1.6)       42.3 ± 11.0   0.0001      30.2 ± 8.5   0.0002
  Plasminogen                 A/G/S/FII (6.6)   18.2 ± 11.9   0.07        20.3 ± 6.4   0.0008
  TFPI                        A/G               0             0.5         24.8 ± 5.5   0.009
  D-dimer                     FV/G/S (5.3)      0             0.5         7.5 ± 3.6    0.13
  Prothrombin fragment F1.2   R                 0             0.5         R            ---

R, removed from the model.

Adjusted for age (A), FII G20210A (FII), FV G1691A (FV), sex (G), use of oral contraceptives (H), and smoking (S).

###### 

Comparison of h^2^r and c^2^ estimates.

  Our study                   SAFHS ([@b26-ehp0116-000839])                       Gait ([@b38-ehp0116-000839])   United Kingdom ([@b3-ehp0116-000839]; [@b8-ehp0116-000839])   Vermont ([@b44-ehp0116-000839])                       United Kingdom ([@b33-ehp0116-000839])   Münster (Nowak-Göttl et al. 2008)                                                                                                                                                                                                                                                                             
  --------------------------- --------------------------------------------------- ------------------------------ ------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------- ----------------------------------- ----------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Lp(a)                       69[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   5                              ---                                                           ---                                                   ---                                      ---                                 ---                                                   ---                                                   ---                                                 ---                                                 84.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   0.4
  Cholesterol                 39[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   4                              ---                                                           ---                                                   ---                                      ---                                 ---                                                   ---                                                   40[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   8[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}    9.3                                                   16.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  HDL                         45[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   2                              ---                                                           ---                                                   ---                                      ---                                 ---                                                   ---                                                   ---                                                 ---                                                 15.7[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   9.4
  LDL                         40[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   7                              ---                                                           ---                                                   ---                                      ---                                 ---                                                   ---                                                   ---                                                 ---                                                 24.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   10.2
  Fibrinogen                  ---                                                 ---                            33.6[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}           13.7[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   44                                       0                                   29.7[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   0                                                     23                                                  16[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   22.5[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   11.7[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  FII                         ---                                                 ---                            49.2[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}           0                                                     57                                       0                                   70[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     4.1                                                   ---                                                 ---                                                 0                                                     20.8[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  FV                          ---                                                 ---                            44[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}             13[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     ---                                      ---                                 71.4[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   2.8                                                   ---                                                 ---                                                 0                                                     9.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  FVIIIC                      ---                                                 ---                            40[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}             0                                                     ---                                      ---                                 ---                                                   ---                                                   ---                                                 ---                                                 5.9                                                   12.1
  vWF                         ---                                                 ---                            31.8[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}           0                                                     75                                       0                                   25.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   30.7[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   ---                                                 ---                                                 23.4                                                  15.8[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  Antithrombin                ---                                                 ---                            48.6[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}           0                                                     ---                                      ---                                 6                                                     33.5[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   ---                                                 ---                                                 0                                                     30.0[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  Protein C                   ---                                                 ---                            50[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}             0                                                     ---                                      ---                                 40.6[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   4.4                                                   ---                                                 ---                                                 17.7[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   20.1[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  Protein S                   ---                                                 ---                            22[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}             21[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     ---                                      ---                                 10.5                                                  37[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     ---                                                 ---                                                 14.9                                                  33.2[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  Protein Z                   ---                                                 ---                            ---                                                           ---                                                   ---                                      ---                                 67[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     6.6                                                   ---                                                 ---                                                 42.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}   30.2[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  Plasminogen                 ---                                                 ---                            23.6[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}           0                                                     ---                                      ---                                 ---                                                   ---                                                   ---                                                 ---                                                 18.2                                                  20.3[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  TFPI                        ---                                                 ---                            51.6[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}           0                                                     ---                                      ---                                 ---                                                   ---                                                   ---                                                 ---                                                 0                                                     24.8[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}
  D-dimer                     ---                                                 ---                            10.9                                                          0                                                     65                                       ---                                 7                                                     5.2                                                   ---                                                 ---                                                 0                                                     7.5
  Prothrombin fragment F1.2   ---                                                 ---                            ---                                                           ---                                                   45                                       ---                                 22[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     44[\*](#tfn8-ehp0116-000839){ref-type="table-fn"}     ---                                                 ---                                                 0                                                     R

Abbreviations: ---, no data; max, maximum; min, minimum; R, removed from the model; SAFHS, San Antonio Family Heart Study.

*p* \< 0.05.
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